Skip to content

Feasibility of a Trial Evaluating the Effectiveness of Occupational Therapy in Parkinson's Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01010529
Acronym
OTiP pilot
Enrollment
43
Registered
2009-11-10
Start date
2009-10-31
Completion date
2010-06-30
Last updated
2011-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Occupational Therapy, Parkinson's Disease, Feasibility, Effectiveness, RCT, Activities of daily living, Participation, Caregiver's Burden

Brief summary

The purpose of this study is to determine the feasibility of a RCT evaluating the effectiveness of occupational therapy in Parkinson's disease.

Detailed description

Parkinson's disease is a complex disabling condition progressively affecting activities and participation of patients. Occupational Therapy aims to optimise functional performance and engagement in meaningful roles and activities. The lack of scientific evidence for the effectiveness of Occupational Therapy (OT) in Parkinson's Disease (PD) highlights the urgent need for high quality intervention studies. The recently developed Dutch clinical practice guideline for OT in PD offers a good basis for conducting an intervention study. This proposed pilot study is an important step towards setting up a large scale RCT to evaluate the effectiveness of OT in improving daily functioning of patients with PD and reducing caregivers' burden.

Interventions

OTHERoccupational therapy

Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.

Sponsors

Stichting Nuts Ohra
CollaboratorOTHER
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

patients: * idiopathic Parkinson's Disease according to UK Brain Bank Criteria * home dwelling * indication for occupational therapy (according to criteria in the evidence based guideline) Inclusion criteria caregivers: * available to provide informal support minimal two times a week to a patient who participates in the study.

Exclusion criteria

patients: * not capable of completing the self assessment forms (i.e. due to language or severe cognitive problems) * comorbidity with symptoms that interfere with actively taking part in the intervention (e.g psychosis, severe heart condition). Or limitations in activities are dominated by the co morbid condition rather than by Parkinson's Disease. * current participation in other allied health research (IMPACT, PARKFIT, ERGODIM) * having received occupational therapy intervention in the last 12 months

Design outcomes

Primary

MeasureTime frame
Patient: Combination of AMPS-process skills and COPM-performance measure0 and 3 months
Caregiver: Zarit Burden Inventory (ZBI)0 and 3 months

Secondary

MeasureTime frame
Patient: AMC Linear Disability Scale (ALDS)0 and 3 months
Patient: Parkinson's Disease Questionnaire 39 (PDQ-39)0 and 3 months
Patient: Assessment of Motor and Process Skills(AMPS)- motor skills0 and 3 months
Patient and Caregiver: EQ-5D and VAS0 and 3 months
Patient: Canadian Occupational Performance Measure (COPM)- satisfaction measure0 and 3 months
Caregiver: Canadian Occupational Performance Measure (COPM)0 and 3 months
Caregiver: Questionnaire Objective Caregiving Burden0 and 3 months
Caregiver: SF-360 and 3 months
Patient and caregiver in intervention group: satisfaction with intervention3 months
Patient and caregiver: Resource utilization0 and 3 months
Patient: Impact on Participation and Autonomy (IPA)0 and 3 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026